Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C21 Investments's EBIT per Share for the
three
months ended in Mar. 2026 was $0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02.
During the past 12 months, the average EBIT per Share Growth Rate of C21 Investments was 73.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -15.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -33.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for C21 Investments's EBIT per Share or its related term are showing as below:
CXXIF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -109.3 Med: 6.05 Max: 45.1
Current: -15.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of C21 Investments was 45.10% per year. The lowest was -109.30% per year. And the median was 6.05% per year.
CXXIF's 3-Year EBIT Growth Rate is ranked worse than 81.4% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs CXXIF: -15.40
C21 Investments's EBIT for the
three
months ended in Mar. 2026 was $0.55 Mil.
C21 Investments (OTCPK:CXXIF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
C21 Investments EBIT per Share Related Terms
C21 Investments EBIT per Share Historical Data
* Premium members only.
The historical data trend for C21 Investments's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a EBIT per Share of $0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on C21 Investments and its competitors. According to the industry distribution chart, C21 Investments ranks #661 out of 812 companies in the Drug Manufacturers industry, placing it in the top 81.4%.
Is C21 Investments' EBIT per Share too high?
C21 Investments' current EBIT per Share is $0.02. The Drug Manufacturers industry median EBIT per Share is 7.45. C21 Investments' value of $0.02 is 99.7% below this industry median. Based on the distribution chart, C21 Investments ranks #661 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #661 out of 812 companies for EBIT per Share. This places C21 Investments in the lower half of its industry. The industry median EBIT per Share is 7.45. C21 Investments' value of $0.02 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.45, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current EBIT per Share of $0.02 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current EBIT per Share is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.23 — trading 18.8% below its estimated fair value. The current EBIT per Share is $0.02 and 99.7% below the Drug Manufacturers industry median of 7.45. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For C21 Investments (CXXIF), the current EBIT per Share is $0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.23 is trading 18.8% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
EBIT per Share: $0.02
GF Value™: $0.28 vs. price of $0.23 (18.8% below fair value)
Industry Position: 99.7% below the Drug Manufacturers median (#661 of 812)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
